Drug Profile
Fosaprepitant - Merck & Co
Alternative Names: Emend For Injection; Emend IV; Fosaprepitant dimeglumine; IVEmend; MK-0517; MK-517; ONO-7847; ProemendLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Merck & Co
- Developer Merck & Co; Ono Pharmaceutical
- Class Antiemetics; Fluorinated hydrocarbons; Morpholines; Phosphonic acids; Small molecules; Triazoles
- Mechanism of Action Neurokinin 1 receptor antagonists; Substance P inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Chemotherapy-induced nausea and vomiting
- No development reported Postoperative nausea and vomiting
Most Recent Events
- 02 Aug 2022 Launched for Chemotherapy-induced nausea and vomiting (In adolescents, In children, In infants, In neonates) in USA (IV) before August 2022 (Merck & Co pipeline, August 2022)
- 02 Aug 2022 Registered for Chemotherapy-induced nausea and vomiting (In adolescents, In children, In infants, In neonates) in USA (IV) before August 2022 (Merck & Co pipeline, August 2022)
- 19 Feb 2021 Launched for Chemotherapy-induced nausea and vomiting in Finland, Denmark, France, Belgium (IV) before February 2021